Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive tumor microenvironment (TME) and poor prognosis. Although major histocompatibility complex class II (MHC-II) is typically expressed by professional antigen-presenting cells, its regulation and significance in malignant PDAC cells remain un...
Can-Ping Chen, Yi Zhang, Xi Li et al.· Cancer immunology research· 0 citations
Pancreatic adenocarcinoma (PDAC) is an abysmal disease, with a poor clinical outcome, largely due to limited life-extending treatments for patients. Notoriously, PDAC displays a T cell-suppressive tumor microenvironment where underlying molecular mechanisms that lead to this phenotype remain poorly understood. To unr...
Kimberly A. Kelly, Cody L. Wolf, Roxanne K. Ruiz et al.· Cancer Research· 0 citations
Plectin is identified as a biomarker of aggressive disease in PDAC, with high plectin expression associated with decreased T cell infiltration, and anti-CSP treatment reinstates antitumor immunity and decreases tumor volume in vivo.
Cody L. Wolf, Roxanne K. Ruiz, Sokchea Khou et al.· Frontiers in Immunology· 0 citations
Overall, it is found that the post-transcriptional regulator HuR facilitates immune evasion in PDAC by constraining T-cell function, identifying HuR blockade as a promising therapeutic strategy in combination with immunotherapies.
Yi-Fei Guo, Jennifer M. Finan, Alexandra Q. Bartlett et al.· Cancer immunology research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
